Odactra Tablet
NDC Package 52709-1701-3
Package Information
Odactra (dermatophagoides pteronyssinus and dermatophagoides farinae) tablets is ODACTRA™ is an allergen extract indicated as immunotherapy for house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites, or skin testing to licensed house dust mite allergen extracts. This formulation utilizes a tablet delivery system. Marketed by Alk-abello A S, this product is identified by NDC 52709-1701 and is authorized under FDA application BLA125592.
Identification & Billing
Clinical Specifications
- Allergens - [CS]
- Allergens - [CS]
- Antigens, Dermatophagoides - [CS]
- Cell-mediated Immunity - [PE] (Physiologic Effect)
- Increased Histamine Release - [PE] (Physiologic Effect)
- Increased IgG Production - [PE] (Physiologic Effect)
- Insect Proteins - [CS]
- Standardized Insect Allergenic Extract - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 52709 - Alk-abello A S
- 52709-1701 - Odactra
- 52709-1701-3 - 3 BLISTER PACK in 1 CARTON / 10 TABLET in 1 BLISTER PACK (52709-1701-1)
- 52709-1701 - Odactra
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (52709-1701). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 52709-1701-3 identifies a specific commercial package of 3 blister pack in 1 carton / 10 tablet in 1 blister pack (52709-1701-1) of Odactra, a standardized allergenic label labeled by Alk-abello A S. This tablet is formulated for sublingual use and contains dermatophagoides farinae; dermatophagoides pteronyssinus as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Alk-abello A S on January 01, 2018. The current certification is valid through December 31, 2027.
How is this Alk-abello A S product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 52709170103. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 3 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.